NOR-101 / North Immunology - LARVOL DELTA

North Immunology opts for reverse merger, $180M raise to drive atopic dermatitis ambitions (Firstwordpharma Press Release) - "NOR-101 is a half-life extended anti-IL-13/IL-18 bispecific antibody designed to inhibit both the type 2 and non-type 2 inflammation that drives atopic dermatitis. A Phase Ia trial of NOR-101 is set to begin in the first quarter of 2027, with interim data expected mid-year...Under the agreed terms, pre-merger Aethlon stockholders are expected to own approximately 4.75% of the combined company, with the remainder to be held by pre-merger North Immunology shareholders. In addition, Aethlon stockholders will receive a contingent value right entitling them to proceeds from any sale or deal around the firm's legacy Hemopurifier business."

M&A • Atopic Dermatitis • Inflammation